Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

NCT03335254 is registered in ClinicalTrials.gov with TesoRx Pharma, LLC as lead sponsor.

NCT NCT03335254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03335254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
Lead sponsor
TesoRx Pharma, LLC
Phase
Phase 1/2
Overall status
Terminated
Start date
November 6, 2017
Completion date
May 3, 2018
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, gonadal disorders, hypogonadism, hypogonadism, male, testosterone deficiency